Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069304

SCHEMBL21069304

SCHEMBL21069304

CC(C)(C)OC(=O)NC1CC(OCCOS(C)(=O)=O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.42
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CTSK P43235 2/20 0.36
▸ GAA P10253 2/20 0.35
▸ MAOB P27338 2/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ EPHX1 P07099 1/20 0.35
▸ EPHX2 P34913 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ CA12 O43570 1/20 0.32
▸ CA7 P43166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24607968 1.00 BTK (0.42) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL22849719 0.92 BTK (0.40) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL21997117 0.92 BTK (0.40) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL21069885 0.81 BTK (0.47) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL24607967 0.81 BTK (0.47) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL28515807 0.81 BTK (0.43) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL21071050 0.81 BTK (0.39) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL21070922 0.81 BTK (0.39) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL20690429 0.80 BTK (0.46) BTKKMT2AL3MBTL1CTSKGAA
SCHEMBL1498559 0.80 BTK (0.48) BTKKMT2AL3MBTL1CTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 — — EP disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-30 — — US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BTK 27/4885KMT2A 445/4885L3MBTL1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.